Taisho Toyama Pharmaceutical Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Toyama Japan (2002)
Status: Acquired by Fujifilm (2008)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (9)

Key: Taisho Toyama Pharmaceutical Ltd. (0) Acquired (9)

azithromycin (zithromax) (1 trial)

diclofenac (voltaren) (1 trial)

esflurbiprofen (1 trial)

favipiravir (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

ozoralizumab (1 trial)

t-614 (1 trial)

ts-142 (14 trials)

zinc sulfate (1 trial)

Drugs in Phase 2 Trials (5)

Key: Taisho Toyama Pharmaceutical Ltd. (0) Acquired (5)

t-817ma (4 trials)

ts022 (1 trial)

ts-091 (2 trials)

ts-121 (2 trials)

ts-161 (2 trials)

Drugs in Phase 1 Trials (8)

Key: Taisho Toyama Pharmaceutical Ltd. (0) Acquired (8)

itraconazole (sporanox) (1 trial)

moxifloxacin (avelox) (1 trial)

pf-04802540 (3 trials)

tasp0410699 (1 trial)

ts-134 (3 trials)

ts-143 (3 trials)

ts-172 (1 trial)

zopiclone (Zimovane) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 39
  • # of Trial APIs: 22